
OPRX
USDOptimizeRx Corporation Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$18.900
High
$19.383
Low
$18.689
Volume
0.42M
Company Fundamentals
Market Cap
356.4M
Industry
Health Information Services
Country
United States
Trading Stats
Avg Volume
0.37M
Exchange
NCM
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Oct 30, 2025OPRX Analysis: Navigating OptimizeRx's Volatile Growth Path
Recent Price Movements
- July-August Transition: Shares jumped 37% on August 8 (12.84→17.30) with volume 5x average
- September Rally: Steady climb from 17.16 (Sept 2) to 20.51 (Sept 29) - 19.5% gain
- Current Position: Trading at $20.56 (Oct 29) after hitting $22.25 weekly high
- Pattern Alert: 3 failed attempts to hold above $22 since late September
Key Catalysts
- October 10 Analyst Boost: JMP Securities raised target to $23 (+15% from current)
- AI Prediction Signals:
- Short-term projections: +1.1% (D1), +1.7% (D2), +2.5% (D3)
- High-confidence bullish signal (81.1% AI confidence)
- Volume Surges: 3 recent spikes (584k on Aug 28, 662k on Sept 29, 421k on Oct 24)
Strategic Considerations
Strengths
- Explosive revenue growth (55.2% YoY)
- Strong institutional interest (4.9x average volume days)
- Healthcare tech positioning in growing sector
Concerns
- Profitability challenges (Negative ROE: -8.2%)
- Heavy debt load (24.29 Debt/Equity ratio)
- Technical resistance at $22 level
Actionable Insights
- Entry Window: Current price ($20.56) near support level ($20.55)
- Trade Parameters:
- Stop Loss: $18.48 (10% downside protection)
- Take Profit: $22.50 (9.4% upside)
- Alternative Entries: $20.64-$21.08 range
- Holding Strategy: 1-2 week horizon aligns with AI predictions
Final Perspective
OptimizeRx presents a high-growth opportunity tempered by financial health concerns. The combination of analyst upgrades, AI bullishness, and technical support near current levels creates a favorable risk/reward scenario for short-term traders. Long-term investors should monitor debt management and profitability improvements.
Disclaimer: This analysis references historical data and AI predictions that may not reflect future performance. Consult a financial advisor before making investment decisions. Past performance does not guarantee future results.
Related News
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
JMP Securities analyst Constantine Davides maintains OptimizeRx with a Market Outperform and raises the price target from $20 to $23.
AI PredictionBeta
AI Recommendation
Updated at: Nov 4, 2025, 05:09 PM
65.0% Confidence
Risk & Trading
Entry Point
$19.62
Take Profit
$20.97
Stop Loss
$17.52
Key Factors
Related Stocks
SQFTP
Presidio Property Trust Inc. 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock $0.01 par value per share
CGBDL
Carlyle Secured Lending Inc. 8.20% Notes due 2028
QUIK
QuickLogic Corporation
LIND
Lindblad Expeditions Holdings Inc.
LUXHP
LuxUrban Hotels Inc. 13.00% Series A Cumulative Redeemable Preferred Stock
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.